Dr James Smith wrote: "The significance of a product demonstrably free of hepatitis risk cannot be ignored and it is essential that BPL/PFL be well placed to take advantage of such developments."
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Viral Inactivation
Key Person(s)
Dr James K Smith